TL;DR

101 scored market entries reviewed across 10 transparency dimensions via live page fetches. This audit includes substitute entries where original brand targets could not be verified consistently from public-facing information. Scores reflect visible consumer-facing transparency signals available at the time of review.

Education-only orientation. This is not medical, legal, dosing, sourcing, purchasing, or product-use advice. It does not tell readers where or how to obtain any substance. The page reviews public-facing transparency signals and consumer-information standards only.

What this page does and does not contain. This page discusses labeling, testing visibility, ingredient disclosure, claim restraint, and public-facing safety language. It does not evaluate product effectiveness, recommend products, verify product contents, or make legal conclusions about any brand.

Key concepts
Transparency score
A public-facing signal score derived from visible consumer-facing information — not a product quality or safety certification.
Scored market entry
A brand or product-page reviewed under the 100-point framework using publicly accessible information available at the time of review.
COA visibility
How easily a consumer can find current, batch-specific lab documentation from a product page before purchase.
Substitute entry
An independently verified brand included where an originally catalogued brand could not be confirmed as a real, publicly accessible US market entity.

Affiliation and scoring disclosure. iMicrodosing.org is an education-focused property. iMicrodosing.com is an affiliated eCommerce property and is included in this audit for transparency. Its score was calculated using the same public-facing criteria applied to other entries. Inclusion does not turn this report into a product recommendation, safety certification, legal conclusion, or verification of product contents.

Audit methodology. Every score in this audit derives from live page fetches of brand product pages, shipping/policy pages, and about pages, plus direct checks of Trustpilot and BBB profiles. No brand is scored from search snippets or roundup articles alone. Each dimension score cites the specific page URL and the exact language or evidence that justified it.

Publication status. This audit includes 101 scored market entries, including substitute entries where original brand targets could not be verified consistently from public-facing information. All entries are scored and verified from live page fetches. Scores reflect visible consumer-facing transparency signals available at the time of review.

Full scorecard. This page contains the complete scored record for all 101 audit entries, with per-dimension scores and evidence notes for each entry. For a summary of methodology and key findings, see the 2026 Mushroom Wellness Transparency Report overview.


Audit Methodology

Per-Brand Process

Each brand in this audit received a minimum of four live page fetches before any dimension was scored:

  1. Main product page (representative product or category page)
  2. Shipping, policy, or returns page
  3. About or company page
  4. COA or lab testing page where separately hosted
  5. Trustpilot profile (search + fetch)
  6. BBB profile (search)

Evidence for every score is documented inline with the source URL and quoted or paraphrased language from the fetched page. Scores are not adjusted based on brand reputation, market position, or prior knowledge. If a page was blocked or returned insufficient information, the dimension is marked partial with explanation rather than estimated.

Status Definitions

Verified — All dimensions scored from live fetched pages with evidence documented. Partial — Some pages fetched; some blocked or insufficient. Score reflects confirmed evidence only. Pending — Live fetches not yet completed. No score assigned. Unverifiable — No live pages accessible; cannot score any dimension.


Summary of Findings

This audit reviewed 101 scored market entries across three mushroom wellness product categories — functional supplements, Amanita/muscimol products, and psilocybin-adjacent nootropic blends — using a 100-point scoring framework applied uniformly from live page fetches. The audit includes substitute entries where originally catalogued brands could not be verified as real, publicly accessible US market entities.

Batch-level averages — all 101 scored entries
BatchCategoryEntriesAvg ScoreGradeNotes
1Functional Supplements 1–101067/100CReal Mushrooms leads at 86/100
2Functional Supplements 11–201050/100DNammex (B2B) excluded from avg
3Functional Supplements 31–401049/100DMyco CLINIC (B2B) excluded from avg
3bFunctional Supplements 21–301041/100DLowest functional-supplement batch avg
4Amanita / Muscimol 41–501051/100DFirst Amanita batch; 3 entries lacked disclosed Amanita content
5Amanita / Muscimol 51–601047.5/100FBlue Forest Farms: active FDA adulteration finding
6Amanita / Muscimol 61–701043.7/100FMost severe cataloguing-failure batch; 12 of 13 original brands unverifiable
7Amanita gap + Nootropic 71–801049.6/100D5 of 10 original brands failed verification
8Psilocybin-Adjacent 81–901048.0/100F7 of 10 original brands required correction or substitution
9Psilocybin-Adjacent 91–1001055.7/100DHighest substitution rate of any batch (8 of 10)
101iMicrodosing.com (affiliated)180/100BCluster eCommerce; see affiliation disclosure

Key Cross-Batch Findings

COA visibility is the sharpest dividing line. Fewer than 20% of audited entries link a batch-specific, accredited third-party COA from the product page before purchase. Most “lab tested” claims consist of a badge or assertion without a verifiable document. Brands in the upper score tier uniformly provide direct product-page COA links. [1] Government Current Good Manufacturing Practice (CGMP) Regulations for Dietary Supplements U.S. Food and Drug Administration (2023) Link →

Medical-claim restraint failures are widespread. A majority of psilocybin-adjacent and Amanita-category entries use language that implies consciousness-altering outcomes without naming the active compound responsible, or makes structure/function claims that exceed what the disclosed ingredient panel can support. [2] Government Health Products Compliance Guidance Federal Trade Commission (2022) Link →

Brand identity and domain integrity problems are systemic in Amanita and nootropic categories. Across Batches 4–9, the majority of originally catalogued brands required domain correction or full substitution. Several original catalogue entries resolved to gambling spam, unrelated industries, Canadian psilocybin sellers, or brands with no Amanita product on their current catalog at all.

The Diamond Shruumz recall defines the floor of this category. One entry (Brand 56 substitute, Blue Forest Farms) is the subject of an active FDA Warning Letter formally determining its products adulterated under federal law. Diamond Shruumz, originally catalogued in Batch 7, is now inactive — its 2024 nationwide recall followed 180+ illnesses and associated deaths. [3] Government Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) U.S. Food and Drug Administration (2024) Link → [4] Government Multistate Outbreak of Adverse Events Associated with Products Containing Muscimol Centers for Disease Control and Prevention (2024) Link →

Full Scored Data

Per-entry dimension scores, evidence notes, and source URLs for all 101 scored entries are available in the interactive scorecard.

Full scored data. Per-entry dimension scores, evidence notes, and source URLs for all 101 scored entries are documented in the 2026 Mushroom Wellness Transparency Report overview.

iMicrodosing.com — Cluster eCommerce Site

imicrodosing.com · Psilocybin-Adjacent · Grade B · 80/100 Independently verified through multiple live fetches and client-provided COA screenshots. Full evidence documented separately.

iMicrodosing.com — final verified scorecard
DimensionScoreEvidence basis
COA Visibility8/10Product-specific batch COAs live on site. Rose City Labs ANAB/ILAC-MRA Cert #L2467-01. Batch IDs visible (RCL-030526-002/003, RCL-020926-001). COA ✅ Available on all product pages.
Lab Panel Clarity8/10Full panel: psilocybin + psilocin (HPLC-UV), aerobic plate count, yeast & mold, E. coli, Salmonella, heavy metals (Pb/As/Cd/Hg via ICP-MS), moisture (AOAC). OVERALL RESULT: PASS.
Ingredient Transparency7/10StrainOne: Albino Penis Envy (APE), Psilocybe cubensis named. Targeted Capsules: 400mg psilocybin blend + 200mg natural active complex stated. Adjunct layer proprietary.
Dosage Clarity8/10150/250/400/600mg strengths stated. Recommended schedules per product. Assessment tool linked. Introductory vs. structured protocols defined.
Medical Claim Restraint9/10Zero disease-treatment claims on commerce pages. Functional orientation language: “support sustained attention,” “support emotional steadiness.” Professional consultation note on every product.
Legal Disclaimers7/1021+ gate sitewide. Legal context handled by imicrodosing.net cluster property. −3: not surfaced on commerce pages directly.
Support Availability9/10Named CEO (Mikhail Lev) and Director of Operations (Sofiya Remezov) via BBB. About page. Email on every product. Live Chatra widget. 24/7 support. Free consultations.
Shipping Transparency9/10Dedicated page. Mon–Sat, 2PM PST cutoff, free domestic, UPS/USPS, 3-day avg, expedited tiers ($20/$35/$75), Friday overnight caveat, replacement for lost orders. Best-in-audit.
Review Visibility7/10BBB Accredited 3/24/2026 (iEssentials LLC). 9 Google Business Profiles. Trustpilot. Client Conversations page.
Refund/Replacement8/10Dedicated page. No refunds on edibles. Replacement for confirmed-lost orders, no forms. Missing items addressed.
Total80/100Grade B


Corrections and updates. Scores reflect public-facing information available at the time of review. Brands may update labels, COAs, ingredient panels, legal disclosures, or claim language after publication. If a brand believes a score should be reviewed, it may request correction by identifying the specific public-facing page, document, or label language that changed.

Frequently Asked Questions

Corrections and updates. Scores reflect public-facing information available at the time of review. Brands may update labels, COAs, ingredient panels, legal disclosures, or claim language after publication. If a brand believes a score should be reviewed, it may request correction by identifying the specific public-facing page, document, or label language that changed.

How were brands scored?

Every brand in this audit was scored via live page fetches of their product pages, shipping/policy pages, and about pages, plus direct checks of Trustpilot and BBB profiles. No brand was scored from search snippets or roundup articles alone. Each dimension score cites the specific URL and evidence that justified it.

How were brands selected?

Brands were identified through systematic search discovery across all three mushroom product categories — functional supplements, Amanita/muscimol products, and psilocybin-adjacent nootropic blends — targeting US-market brands with publicly accessible product pages. The goal was a broad market cross-section, not a curated best-of list. iMicrodosing.com (cluster eCommerce) was included and scored on the full standard rubric.

What does 'Unverifiable' mean?

A brand is flagged Unverifiable when its product page was inaccessible, required authentication or purchase to view basic information, or provided insufficient publicly visible information to score any dimension meaningfully. Unverifiable brands receive no numerical score and are excluded from aggregate statistics.

Does a high score mean a product is safe or effective?

No. The score measures how clearly a company communicates what a consumer needs to know from publicly visible information. A high-scoring brand may still carry product risks. A low-scoring brand is not automatically unsafe. This audit evaluates disclosure quality only.

Why is iMicrodosing.com included?

iMicrodosing.com is the eCommerce arm of the cluster that publishes this report. It is scored on the full 100-point standard rubric with no adjustments. Being part of the publishing cluster creates an obligation to apply the same standard rigorously — no special treatment in either direction.